Brind.
  1. Eli Lilly and Company is expanding into psychedelic and neuroscience pipelines, adding late-stage psychedelic assets through acquisition.

Eli Lilly acquires AtaiBeckley to advance psychedelic depression treatment

1 report, 1 independent Updated Sat 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Eli Lilly and Company completed the acquisition of drugmaker AtaiBeckley. AtaiBeckley is conducting clinical trials on bufotenin, a psychedelic compound, for treating depression. In phase 2b trials, low and high doses of the drug helped over 34% of participants who had depression and had not responded to previous antidepressants.

From nypost.com

Why it matters

Some supportBrind's analysis of the reports

The acquisition supports Eli Lilly and Company's expansion into psychedelic and neuroscience pipelines. Bufotenin is being studied as a potential new treatment for depression, a disorder that affects roughly one in six American adults.

Eli Lilly and Company is expanding into psychedelic and neuroscience pipelines, adding late-stage psychedelic assets through acquisition.

From nypost.com

Who's involved

  • Eli Lilly and CompanyAmerican pharmaceutical company expanding its neuroscience pipeline through acquisition

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

Keep exploring

Part of

Eli Lilly and Company is expanding into psychedelic and neuroscience pipelines, adding late-stage psychedelic assets through acquisition. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped